Workshop Presented Overwhelming Scientific Evidence to Support CSF-HS as a Primary Biomarker in Neuropathic MPS DisordersWASHINGTON, DC / ACCESSWIRE /…
Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic…
Learn more during Kidney Health Month in MarchMontreal, Quebec--(Newsfile Corp. - February 29, 2024) - When the Kidney Foundation of…
After years of successful collaboration, the esteemed organizations National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA) have…
CHICAGO, IL / ACCESSWIRE / February 29, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value…
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to…
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality…
Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:…